TBPH Stock Analysis: Buy, Sell, or Hold?
TBPH - Theravance Biopharma, Inc.
$17.01
0.06 (0.35%)
▲
5d:
+0.24%
30d:
+0.89%
90d:
+4.1%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When TBPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TBPH shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TBPH shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$32.53
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$20.20
15.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TBPH is currently trading at $17.01, which is considered extended relative to its 30-day fair value range of $16.85 to $16.95. The stock's valuation (Forward PE: 13.3) is in line with its historical norms (13.1). At these levels, the market is pricing in 0.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TBPH is in a uptrend. The price is currently testing key support at $16.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TBPH is in a uptrend. The price is currently testing key support at $16.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$16.85 -
$16.95
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.1%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($17.67)
- NEUTRAL: Market pricing in 0.5% annual earnings growth - fairly valued
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$16.85 -
$16.95
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$16.88
Resistance Level
$17.02
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.34
Wall Street Target
$17.67
(+3.9%)
Revenue Growth (YoY)
-20.9%
Profit Margin
51.6%
Valuation Premium vs History
+0.5% premium
PE vs Historical
13.3 vs 13.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.5%
(market-implied from PE analysis)
1-Year Target
$17.10
(+1%)
2-Year Target
$17.18
(+1%)
3-Year Target
$17.27
(+2%)
3-Yr Target (if PE normalizes)
(PE: 13→13)
PE COMPRESSION
$16.95
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 507.1%)
$86.36
(+408%)
Base:
(SPY PE: 13.3, Growth: 507.1%)
$57.41
(+238%)
Bear:
(PE: 11.3, Growth: 507.1%)
$48.80
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 16.30 | Current EPS (TTM): $1.04
Bull Case
$22.86
(+34%)
Analyst growth 22.6%, PE expands to 17.9
Base Case
$20.78
(+22%)
Market implied 22.6%, PE stable at 16.3
Bear Case
$11.53
(-32%)
Severe decline -20.0%, PE contracts to 13.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 24, 2026 6:41 AM ET
Data refreshes hourly during market hours. Next update: 7:41 AM
Data refreshes hourly during market hours. Next update: 7:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TBPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Rhonda Farnum
SELL
31067 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 37 SELL |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 50 HOLD |
